Isomorphic Labs reportedly seeking funding at $40–50 billion valuation
Alphabet's AI drug discovery unit, Isomorphic Labs, is reportedly seeking funding at a $40 billion valuation; another report cites $50 billion. The London-based DeepMind spinout also uses AI agents in drug design.
Who is affected and how
- pharmaceuticals
- Huge valuations for AI-native drug developers could redraw the partnership and competitive landscape.
Sources
- Alphabet's AI Drug Discovery Unit Isomorphic Labs Reportedly Seeking Funding at $40 Billion Valuationbiggo finance · Oct 8, 2026
- Alphabet’s Isomorphic Labs in Funding Talks for at Least $40 Billion Value - Bloombergbloomberg.com · Oct 8, 2026
- Valued at no less than $40 billion! Isomorphic Labs, Alphabet’s AI-driven drug discovery company, is in financing negotiations.富途牛牛 · Oct 8, 2026
- Isomorphic Labs Raised $2.1 Billion in Series B Funding in May | TokenPosttokenpost.com · Oct 8, 2026
- Alphabet's Isomorphic in Talks for $40B Valuationel-fondo.com · Oct 8, 2026
- Alphabet's AI-powered drug discovery company, Isomorphic Labs, is in talks for funding, with a valuation of at least $40 billion.allweatherfinance.com · Oct 8, 2026
- Alphabet's AI Drug Discovery Firm Isomorphic Labs in Funding Talks at Valuation of at Least $40 Billion | insigtXinsigtx.com · Oct 8, 2026
- Isomorphic Labs Seeks Funding at $40 Billion Valuation as AI Drug Discovery Advanceskonsulteer · Oct 9, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.